Paul Corn
SWOG Cancer Research Network · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Paul Corn as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:31 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06470243 · Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the BodySWOG Cancer Research Network · recruiting · Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 · principal investigator
- Ph2NCT04754425 · Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate CancerM.D. Anderson Cancer Center · terminated · Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone · principal investigator
- Ph2NCT03821792 · Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate CancerM.D. Anderson Cancer Center · active not recruiting · Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone · principal investigator
- Ph2NCT01994590 · Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)M.D. Anderson Cancer Center · terminated · Prostate Cancer · principal investigator
- Ph2NCT01630590 · Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate CancerM.D. Anderson Cancer Center · completed · Prostate Cancer · principal investigator
- Ph1/Ph2NCT01505868 · Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate CancerM.D. Anderson Cancer Center · completed · Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy · principal investigator
- Ph2NCT01254864 · Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted TherapiesM.D. Anderson Cancer Center · completed · Prostate Cancer · principal investigator
- Ph2NCT00831792 · TKI258 in Castrate Resistant Prostate CancerM.D. Anderson Cancer Center · completed · Prostate Cancer · principal investigator
- Ph1NCT00631527 · Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate CancerM.D. Anderson Cancer Center · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Statewide Alaska Family Network- SAFNetHR1SM059881 · SAMHSA · ALASKA YOUTH FAMILY NETWORK · fiscal years 2011 to 2012Same name and institution; not confirmed by an ID
- Youth Helping Youth Connect with Each Other Through YouthMOVE-AlaskaH79SM059403 · SAMHSA · ALASKA YOUTH FAMILY NETWORK · fiscal years 2010 to 2011Same name and institution; not confirmed by an ID
- Regulation of the von Hippel-Lindau ProteinK08CA093425 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2003 to 2007 · $127,710 awarded in 2007Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2015 to 2026Named on NCT06470243
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2015 to 2026Named on NCT01505868
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:31 UTC. The ranking covers the 200 most relevant of 33 PubMed records, and a shared surname and initials can bring in a namesake. All 33 on PubMed
- Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.J Clin Oncol · 2013353 citationsRCR 9.6
- Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.Nat Med · 2020271 citationsRCR 8.8
- 238 citationsRCR 7.5
- 195 citationsRCR 16.1
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.J Clin Oncol · 2018178 citationsRCR 5.4
- Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.Lancet Oncol · 2019171 citationsRCR 5.6
- Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.J Clin Oncol · 2009158 citationsRCR 3.8
- Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer.Sci Transl Med · 2020134 citationsRCR 4.5
- Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.J Clin Oncol · 2014116 citationsRCR 3.2
- 101 citationsRCR 2.2